66 razones por las que damos positivo al sida sin tener vih: los tests son un timo66

66 RAZONES POR LAS QUE DAMOS POSITIVO

Los propios prospectos de los test del sida dicen que no sirven para detectar el VIH. Nadie ha demostrado que el VIH destruya las células de inmunidad. El test es inespecífico y cualquiera puede dar positivo por tener gripe, hepatitis o CMV, un virus que todos tenemos, que es muchs veces el verdadero causante de la inmunodeficiencia. He aquí algunas de las causas:

​

1. Anticuerpos Anti-carbohidratos 13, 19, 52
2. Anticuerpos naturalmente producidos 5, 19
3. Inmunización pasiva: la recepción de gamma globulina o inmuno globulina (como prevención contra infección que contiene anticuerpos) 4, 13, 18, 22, 26, 42, 43, 60
4. Lepra 2, 25
5. Tuberculosis 25
6. Mycobacterium avium 25
7. Lupus erythematosus sistemático15, 23
8. Falla renal 13, 23, 48
9. Hemodiálisis /falla renal 56, 16,41 10, 49
10. Terapia Alpha interferón en pacientes de hemodiálisis 54
11. GRIPE 36
12. VACUNA PARA GRIPE 30, 11, 3, 20, 13, 43
13. Herpes simple I 27
14. Herpes simple II 11
15. Infección del tracto respiratorio superior (resfriado o influenza) 11
16. Infección viral reciente o exposición a vacunas virales 11
17. Embarazo en mujeres que han tenido parto múltiple 13, 36, 43, 53, 58
18. Malaria 6, 12
19. Altos niveles de complejos inmunes en la circulación sanguinea6, 33
20. Hypergammaglobulinemia (altos niveles de anticuerpos) 33, 40
21. Falsos resultados positivos en otros exámenes, incluyendo RPR para sífilis 10, 17, 33, 48, 49
22. Artritis reumatoide 36
23. Vacuna de Hepatitis B 21, 28, 40,43
24. Vacuna contra Tétano 40
25. Transplante de Órgano 1, 36
26. Transplante Renal 9, 13, 48, 56
27. Anticuerpos Anti -linfocito 31, 56
28. Anticuerpos Anticolagenos (encontrados en hombres homosexuales, hemofílicos, africanos de los dos sexos con lepra) 31
29. Suero positivo para el factor reumatoide, anticuerpo antinuclear (ambos encontrados en artritis reumatoide y otros auto anticuerpos) 14, 53, 62
30. Enfermedades Autoinmunes 10. 29, 40, 43, 49
31. Lupus erythematosus sistemático, scleroderma, enfermedad de tejido conectivo, dermatomiositis, infecciones virales agudas, infecciones virales de ADN 13, 40, 43, 48, 53, 59
32. Neoplasmas malignos (cánceres) 40
33. Hepatitis alcohólica y enfermedad hepática por alcohol 10, 32, 40, 43, 48, 49 , 53
34. Esclerosis cholangitis primaria 48, 53
35. HEPATITIS 54
36. Sangre “pegajosa” (en africanos) 34, 38, 40
37. Anticuerpos con una alta afinidad para polysterina (usada en los paquetes de prueba) 3, 40, 52
38. Transfusiones de sangre, transfusiones de sangre múltiples 13, 36, 41, 43, 49, 53
39. Mieloma Múltiple 10, 43, 53
40. Anticuerpos HLA (para antígenos leucocitos de clase I y II) 7, 10, 43, 46, 48, 49, 53, 63
41. Anticuerpo antimuscular 48
42. Anticuerpo de Célula Anti-parietal 48
43. Anti-hepatitis A IgM (anticuerpo) 48
44. Anti-Hbc IgM 48
45. Administración de preparaciones inmunoglobulinas para humanos antes de 1985 10
46. HEMOFILIA 10, 49
47. Desordenes y linfoma maligna y hematológicas 9, 13, 43, 48, 53
48. Cirrosis biliar primaria 13, 43, 48, 53
49. Síndrome de Stevens-Johnson 9, 13, 48
50. Fiebre Q asociado con hepatitis 61
51. Especímenes tratados con calor 24, 48, 49, 51, 57
52. Suero Lipemico (sangre con altos niveles de grasa o lípidos) 49
53. Suero Hemolizado (sangre donde la hemoglobina se separa de las células rojas)
54. Hyperbilirubinemia 10, 13
55. Globulinas producidas durante gammopatías policlonal (los cuales se ven en los grupos de riesgo de SIDA) 10, 13, 48
56. Individuos saludables como resultado de reacciones adversas malentendidas 10
57. Ribonucleoproteínas normales en humanos 13, 48
58. OTROS RETROVIRUS 8, 13, 14, 48, 55
59. Anticuerpos Anti-mitocondriales 13, 48
60. Anticuerpos Anti-nucleares 13, 48, 53
61. Anticuerpos Anti-microsomales 34
62. Anticuerpos antígenos leucocitos de célula T 13, 48
63. Proteínas en el papel filtro 13
64. EL VIRUS EPSTEIN-BARR Y CITOMEGALOVIRUS, QUE SON VIRUS UBÍCUOS, 37,62
65. Leishmaniasis Visceral 45
66. Sexo anal receptivo, 39

Y ESTA LA BIBLIOGRAFÍA QUE CONFIRMA LOS FALSOS POSITIVOS:

MÉTODO CIENTÍFICO FRENTE A LA MENTIRA DE LOS TESTS
1. Agbalika F, Ferchal F, Garnier J-P, et al. 1992. False-positive antigens related to emergence of a 25-30 kD protein detected in organ recipients. AIDS. 6:959-962.
2. Andrade V, Avelleira JC, Marques A, et al. 1991. Leprosy as a cause of false-positive results in serological assays for the detection of antibodies to HIV-1. Intl. J. Leprosy. 59:125.
3. Arnold NL, Slade RA, Jones MM, et al. 1994. Donor follow up of influenza vaccine-related multiple viral enzyme immunoassay reactivity. Vox Sanguinis. 67:191.
4. Ascher D, Roberts C. 1993. Determination of the etiology of seroreversals in HIV testing by antibody fingerprinting. AIDS. 6:241.
5. Barbacid M, Bolgnesi D, Aaronson S. 1980. Humans have antibodies capable of recognizing oncoviral glycoproteins: Demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus. Proc. Natl. Acad. Sci. 77:1617-1621.
6. Biggar R, Melbye M, Sarin P, et al. 1985. ELISA HTLV retrovirus antibody reactivity associated with malaria and immune complexes in healthy Áfricans. Lancet. ii:520-543.
7. Blanton M, Balakrishnan K, Dumaswala U, et al. 1987. HLA antibodies in blood donors with reactive screening tests for antibody to the immunodeficiency virus. Transfusion. 27(1):118.
8. Blomberg J, Vincic E, Jonsson C, et al. 1990. Identification of regions of HIV-1 p24 reactive with sera which give “indeterminate” results in electrophoretic immunoblots with the help of long synthetic peptides. AIDS Res. Hum. Retro. 6:1363.
9. Burkhardt U, Mertens T, Eggers H. 1987. Comparison of two commercially available anti-HIV ELISA’s: Abbott HTLV-III ELA and DuPont HTLV-III ELIS,A. J. Med. Vir. 23:217.
10. Bylund D, Ziegner U, Hooper D. 1992 Review of testing for human immunodeficiency virus. Clin. Lab. Med. 12:305-333.
11. Hallakere K, Rapaport M. 1993. False-positive human immunodeficiency virus type 1 ELISA results in low-risk subjects. West. J. Med. 159(2):214-215.
12. Charmot G, Simon F. 1990. HIV infection and malaria. Revue du practicien. 40:2141.
13. Cordes R, Ryan M. 1995. Pitfalls in HIV testing. Postgraduate Medicine. 98:177.
14. Dock N, Lamberson H, O’Brien T, et al. 1988. Evaluation of atypical human immunodeficiency virus immunoblot reactivity in blood donors. Transfusion. 28:142.
15. Esteva M, Blasini A, Ogly D, et al. 1992. False positive results for antibody to HIV in two men with systemic lupus erythematosus. Ann. Rheum. Dis. 51:1071-1073.
16. Fassbinder W, Kuhni P, Neumayer H. et al. 1986. Prevalence of antibodies against LAV/HTLV-III [HIV] in patients with terminal renal insufficiency treated with hemodialysis and following renal transplantation. Deutsche Medizinische Wochenschrift. 111:1087.
17. Fleming D, Cochi S, Steece R. et al. 1987. Acquired immunodeficiency syndrome in low-incidence areas. JAMA. 258(6):785.
18. Gill MJ, Rachlis A, Anand C. 1991. Five cases of erroneously diagnosed HIV infection. Can. Med. Asso. J. 145(12):1593.
19. Healey D, Bolton W. 1993. Apparent HIV-1 glycoprotein reactivity on Western blot in uninfected blood donors. AIDS. 7:655-658.
20. Hisa J. 1993. False-positive ELISA for human immunodeficiency virus after influenza vaccination. JID. 167:989.
21. Isaacman S. 1989. Positive HIV antibody test results after treatment with hepatitis B immune globulin. JAMA. 262:209.
22. Jackson G, Rubenis M, Knigge M, et al. 1988. Passive immunoneutralisation of human immunodeficiency virus in patients with advanced AIDS. Lancet, Sept. 17:647.
23. Jindal R, Solomon M, Burrows L. 1993. False positive tests for HIV in a woman with lupus and renal failure. NEJM. 328:1281-1282.
24. Jungkind D, DiRenzo S, Young S. 1986. Effect of using heat-inactivated serum with the Abbott human T-cell lymphotropic virus type III [HIV] antibody test. J. Clin. Micro.23:381.
25. Kashala O, Marlink R, Ilunga M. et al. 1994. Infection with human immunodeficiency virus type 1 (HIV-1) and human T-cell lymphotropic viruses among leprosy patients and contacts: correlation between HIV-1 cross-reactivity and antibodies to lipoarabionomanna. J. Infect. Dis. 169:296-304.
26. Lai-Goldman M, McBride J, Howanitz P, et al. 1987. Presence of HTLV-III [HIV] antibodies in immune serum globulin preparations. Am. J. Clin. Path. 87:635.
27. Langedijk J, Vos W, Doornum G, et al. 1992. Identification of cross-reactive epitopes recognized by HIV-1 false-positive sera. AIDS. 6:1547-1548.
28. Lee D, Eby W, Molinaro G. 1992. HIV false positivity after hepatitis B vaccination. Lancet. 339:1060.
29. Leo-Amador G, Ramirez-Rodriguez J, Galvan-Villegas F, et al. 1990. Antibodies against human immunodeficiency virus in generalized lupus erythematosus. Salud Publica de México. 32:15.
30. Mackenzie W, Davis J, Peterson D. et al. 1992. Multiple false-positive serologic tests for HIV, HTLV-1 and hepatitis C following influenza vaccination, 1991. JAMA. 268:1015-1017.
31. Mathe G. 1992. Is the AIDS virus responsible for the disease? Biomed & Pharmacother. 46:1-2.
32. endenhall C, Roselle G, Grossman C, et al. 1986. False-positive tests for HTLV-III [HIV] antibodies in alcoholic patients with hepatitis. NEJM. 314:921.
33. Moore J, Cone E, Alexander S. 1986. HTLV-III [HIV] seropositivity in 1971-1972 parenteral drug abusers – a case of false-positives or evidence of viral exposure? NEJM. 314:1387-1388.
34. Mortimer P, Mortimer J, Parry J. 1985. Which anti-HTLV-III/LAV [HIV] assays for screening and comfirmatory testing? Lancet. Oct. 19, p873.
35. Neale T, Dagger J, Fong R, et al. 1985. False-positive anti-HTLV-III [HIV] serology. New Zealand Med. J. October 23.
36. Ng V. 1991. Serological diagnosis with recombinant peptides/proteins. Clin. Chem. 37:1667-1668.
37. VEB: Ozanne G, Fauvel M. 1988. Perfomance and reliability of five commercial enzyme-linked immunosorbent assay kits in screening for anti-human immunodeficiency virus antibody in high-risk subjects. J. Clin. Micro. 26:1496. / CMV: ,” Bronze et al, Clin Infect Dis. 1998,Jul;27(1):221-2).
38. Papadopulos-Eleopulos E. 1988. Reappraisal of AIDS – Is the oxidation induced by the risk factors the primary cause? Med. Hypo. 25:151.
39. Papadopulos-Eleopulos E, Turner V, and Papadimitriou J. 1993. Is a positive Western blot proof of HIV infection? Bio/Technology. June 11:696-707.
40. Pearlman ES, Ballas SK. 1994. False-positive human immunodeficiency virus screening test related to rabies vaccination. Arch. Pathol. Lab. Med. 118-805.
41. Peternan T, Lang G, Mikos N, et al. Hemodialysis/renal failure. 1986. JAMA. 255:2324.
42. Piszkewicz D. 1987. HTLV-III [HIV] antibodies after immune globulin. JAMA. 257:316.
43. Profitt MR, Yen-Lieberman B. 1993. Laboratory diagnosis of human immunodeficiency virus infection. Inf. Dis. Clin. North Am. 7:203.
44. Anki A, Kurki P, Reipponen S, et al. 1992. Antibodies to retroviral proteins in autoimmune connective tissue disease. Arthritis and Rheumatism. 35:1483.
45. Ribeiro T, Brites C, Moreira E, et al. 1993. Serologic validation of HIV infection in a tropical area. JAIDS. 6:319.
46. Sayers M, Beatty P, Hansen J. 1986. HLA antibodies as a cause of false-positive reactions in screening enzyme immunoassays for antibodies to human T-lymphotropic virus type III [HIV]. Transfusion. 26(1):114.
47. Sayre KR, Dodd RY, Tegtmeier G, et al. 1996. False-positive human immunodeficiency virus type 1 Western blot tests in non-infected blood donors. Transfusion. 36:45.
48. Schleupner CJ. Detection of HIV-1 infection. In: (Mandell GI, Douglas RG, Bennett JE, eds.) Principles and Practice of Infectious Diseases, 3rd ed. New York: Churchill Livingstone, 1990:1092.
49. Schochetman G, George J. 1992. Serologic tests for the detection of human immunodeficiency virus infection. In AIDS Testing Methodology and Management Issues, Springer-Verlag, New York.
50. Simonsen L, Buffington J, Shapiro C, et al. 1995. Multiple false reactions in viral antibody screening assays after influenza vaccination. Am. J. Epidem. 141-1089.
51. Mith D, Dewhurst S, Shepherd S, et al. 1987. False-positive enzyme-linked immunosorbent assay reactions for antibody to human immunodeficiency virus in a population of midwestern patients with congenital bleeding disorders. Transfusion. 127:112.
52. Snyder H, Fleissner E. 1980. Specificity of human antibodies to oncovirus glycoproteins; Recognition of antigen by natural antibodies directed against carbohydrate structures. Proc. Natl. Acad. Sci. 77:1622-1626.
53. Steckelberg JM, Cockerill F. 1988. Serologic testing for human immunodeficiency virus antibodies. Mayo Clin. Proc. 63:373.
54. Ungar C, Akpolat T, Ozkuyumcu C, et al. Alpha interferon therapy in hemodialysis patients. Nephron. 67:251.
55. Tribe D, Reed D, Lindell P, et al. 1988. Antibodies reactive with human immunodeficiency virus gag-coated antigens (gag reactive only) are a major cause of enzyme-linked immunosorbent assay reactivity in a bood donor population. J. Clin. Micro. April:641.
56. Ujhelyi E, Fust G, Illei G, et al. 1989. Different types of false positive anti-HIV reactions in patients on hemodialysis. Immun. Let. 22:35-40.
57. Van Beers D, Duys M, Maes M, et al. Heat inactivation of serum may interfere with tests for antibodies to LAV/HTLV-III [HIV]. J. Vir. Meth. 12:329.
58. Voevodin A. 1992. HIV screening in Russia. Lancet. 339:1548.
59. Weber B, Moshtaghi-Borojeni M, Brunner M, et al. 1995. Evaluation of the reliability of six current anti-HIV-1/HIV-2 enzyme immunoassays. J. Vir. Meth. 55:97.
60. Wood C, Williams A, McNamara J, et al. 1986. Antibody against the human immunodeficiency virus in commercial intravenous gammaglobulin preparations. Ann. Int. Med. 105:536.
61. Yale S, Degroen P, Tooson J, et al. 1994. Unusual aspects of acute Q fever-associated hepatitis. Mayo Clin. Proc. 69:769.
62.-Bronze et al (1998)